ELF has joined an exciting new EU project, OPTIMA, which aims to improve treatment for lung, breast and prostate cancers by gathering a large amount of clinical data and using artificial intelligence to analyse it. You can read more about OPTIMA here.

We have produced a survey to help the OPTIMA researchers understand patients’ and carers’ priorities for research. It is aimed at anyone who has received treatment for lung cancer and their carers and families.

The survey should take around 10 to 15 minutes to complete, and is available in Dutch, English, French, German, Greek, Polish, Portuguese, Spanish and Turkish. We plan to add more languages soon.

Complete the survey

If you are interested in getting involved in ELF’s work with lung cancer research then you could join our Patient Advisory Group. Please email clare.williams@europeanlung.org for more information. 







OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

The views communicated within are those of OPTIMA. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.